Latest Healthcare Research Reports

Tag: gestational diabetes market analysis

  • Gestational Diabetes Market Expected To Reach $13.85 Billion By 2030 As Growth Accelerates At 8.7% CAGR

    Gestational Diabetes Market Expected To Reach $13.85 Billion By 2030 As Growth Accelerates At 8.7% CAGR

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Gestational Diabetes Market Value Analysis: What Growth Is Expected Over The Forecast Period?

    The market for gestational diabetes experienced robust expansion historically and is projected to continue its upward trajectory, expanding from $9.11 billion in 2025 to $9.93 billion in 2026, reflecting a compound annual growth rate of 8.9%. This growth during the past period is largely due to several key factors including rising obesity trends, an increase in pregnancies among older women, the implementation of early screening for diabetes, advancements in prenatal care services, and a heightened awareness of complications associated with pregnancy.

    The market for gestational diabetes is poised for significant expansion in the coming years, projected to reach $13.85 billion by 2030, driven by a compound annual growth rate of 8.7%. This projected increase during the forecast period is largely fueled by an escalating incidence of gestational diabetes, the proliferation of digital health monitoring solutions, enhancements in prenatal diagnostic capabilities, a heightened emphasis on preventative care for expectant mothers, and supportive healthcare policies. Key developments anticipated within this timeframe include a greater uptake of blood glucose monitoring systems, augmented utilization of insulin therapy for pregnant individuals, a growing emphasis on managing this condition through lifestyle modifications, the broadening of prenatal screening initiatives, and elevated awareness surrounding maternal health.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

    Gestational Diabetes Market Development Factors: Which Trends Are Supporting Demand?

    The expanding segment of the population classified as obese, characterized by a body mass index (BMI) of 30 or greater and signifying substantial body fat, is poised to be a significant catalyst for the expansion of the gestational diabetes market. This surge in obesity rates is attributable to a confluence of factors including predominantly inactive lifestyles, a greater reliance on energy-dense, processed food items, inherent genetic tendencies, and restricted availability of nutritious food choices and physical activity venues. The management of gestational diabetes holds particular importance for this demographic, given their heightened susceptibility to insulin resistance and accelerated weight gain during pregnancy, scenarios that can precipitate adverse outcomes for both the expectant mother and the developing fetus if not properly addressed. Illustrating this trend, data from the Office for Health Improvement and Disparities, a UK governmental organization, indicated that in England, a notable 64.5% of individuals aged 18 and above were either overweight or obese between 2023 and 2024, a slight increase from the 64.0% recorded in the preceding year (2022-2023). Consequently, the growing prevalence of obesity is a primary determinant in the upward trajectory of the gestational diabetes market.

    Gestational Diabetes Market Segment Landscape: Which Areas Lead Market Development?

    The gestational diabetes market covered in this report is segmented –

    1) By Type: Type A1, Type A2, Other Types

    2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological Treatment

    3) By Administration: Oral, Intravenous, Other Administrations

    4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers

    Subsegments:

    1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes

    2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes

    3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications

    Gestational Diabetes Market Transformation Trends: Which Innovations Are Driving Change?

    Within the gestational diabetes market, leading enterprises are prioritizing the creation of cutting-edge solutions, specifically diagnostic kits, to facilitate swift, precise, and user-friendly early identification of the condition; these kits serve as vital medical instruments for quantifying blood sugar levels and pinpointing instances of impaired glucose tolerance in expectant mothers, thereby supporting prompt diagnosis and effective management. Illustratively, in August of 2024, DirectSens GmbH, a biotechnology firm headquartered in Austria, introduced the XpressGT RUO kit, a diagnostic device engineered for the detection of gestational diabetes, alongside conditions like endometriosis, insulin resistance, and liver ailments, which gauges 2-hydroxybutyrate (2-HB) concentrations in venous blood with high accuracy; this metabolite, a natural byproduct of liver activity, can escalate due to reductive stress, a factor implicated in numerous endocrine and obesity-related health issues, including insulin resistance, and the kit’s compatibility with any standard clinical analyzer enables the generation of results within an impressive 8-minute timeframe, presenting a remarkably expedient diagnostic capability.

    Gestational Diabetes Market Industry Leaders And Market Competition

    Major companies operating in the gestational diabetes market are Sanofi S.A., Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Dexcom Inc, Biocon Limited, Ascensia Diabetes Care Holdings AG, Roche Diabetes Care, Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc, Ypsomed Holding AG, Beta Bionics Inc, Bigfoot Biomedical Inc, Glooko Inc, Philips Healthcare, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Novartis AG, Adocia SA, Daiichi Sankyo Company Ltd

    Access The Complete Gestational Diabetes Market Report:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    Gestational Diabetes Market Regional Distribution: Which Areas Drive Market Expansion?

    North Americawas the largest region in the gestational diabetes market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gestational Diabetes Market Expected To Reach $13.85 Billion By 2030 As Growth Accelerates At 8.7% CAGR

    Gestational Diabetes Market Expected To Reach $13.85 Billion By 2030 As Growth Accelerates At 8.7% CAGR

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Gestational Diabetes Market Value Analysis: What Growth Is Expected Over The Forecast Period?

    The market for gestational diabetes experienced robust expansion historically and is projected to continue its upward trajectory, expanding from $9.11 billion in 2025 to $9.93 billion in 2026, reflecting a compound annual growth rate of 8.9%. This growth during the past period is largely due to several key factors including rising obesity trends, an increase in pregnancies among older women, the implementation of early screening for diabetes, advancements in prenatal care services, and a heightened awareness of complications associated with pregnancy.

    The market for gestational diabetes is poised for significant expansion in the coming years, projected to reach $13.85 billion by 2030, driven by a compound annual growth rate of 8.7%. This projected increase during the forecast period is largely fueled by an escalating incidence of gestational diabetes, the proliferation of digital health monitoring solutions, enhancements in prenatal diagnostic capabilities, a heightened emphasis on preventative care for expectant mothers, and supportive healthcare policies. Key developments anticipated within this timeframe include a greater uptake of blood glucose monitoring systems, augmented utilization of insulin therapy for pregnant individuals, a growing emphasis on managing this condition through lifestyle modifications, the broadening of prenatal screening initiatives, and elevated awareness surrounding maternal health.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

    Gestational Diabetes Market Development Factors: Which Trends Are Supporting Demand?

    The expanding segment of the population classified as obese, characterized by a body mass index (BMI) of 30 or greater and signifying substantial body fat, is poised to be a significant catalyst for the expansion of the gestational diabetes market. This surge in obesity rates is attributable to a confluence of factors including predominantly inactive lifestyles, a greater reliance on energy-dense, processed food items, inherent genetic tendencies, and restricted availability of nutritious food choices and physical activity venues. The management of gestational diabetes holds particular importance for this demographic, given their heightened susceptibility to insulin resistance and accelerated weight gain during pregnancy, scenarios that can precipitate adverse outcomes for both the expectant mother and the developing fetus if not properly addressed. Illustrating this trend, data from the Office for Health Improvement and Disparities, a UK governmental organization, indicated that in England, a notable 64.5% of individuals aged 18 and above were either overweight or obese between 2023 and 2024, a slight increase from the 64.0% recorded in the preceding year (2022-2023). Consequently, the growing prevalence of obesity is a primary determinant in the upward trajectory of the gestational diabetes market.

    Gestational Diabetes Market Segment Landscape: Which Areas Lead Market Development?

    The gestational diabetes market covered in this report is segmented –

    1) By Type: Type A1, Type A2, Other Types

    2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological Treatment

    3) By Administration: Oral, Intravenous, Other Administrations

    4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers

    Subsegments:

    1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes

    2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes

    3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications

    Gestational Diabetes Market Transformation Trends: Which Innovations Are Driving Change?

    Within the gestational diabetes market, leading enterprises are prioritizing the creation of cutting-edge solutions, specifically diagnostic kits, to facilitate swift, precise, and user-friendly early identification of the condition; these kits serve as vital medical instruments for quantifying blood sugar levels and pinpointing instances of impaired glucose tolerance in expectant mothers, thereby supporting prompt diagnosis and effective management. Illustratively, in August of 2024, DirectSens GmbH, a biotechnology firm headquartered in Austria, introduced the XpressGT RUO kit, a diagnostic device engineered for the detection of gestational diabetes, alongside conditions like endometriosis, insulin resistance, and liver ailments, which gauges 2-hydroxybutyrate (2-HB) concentrations in venous blood with high accuracy; this metabolite, a natural byproduct of liver activity, can escalate due to reductive stress, a factor implicated in numerous endocrine and obesity-related health issues, including insulin resistance, and the kit’s compatibility with any standard clinical analyzer enables the generation of results within an impressive 8-minute timeframe, presenting a remarkably expedient diagnostic capability.

    Gestational Diabetes Market Industry Leaders And Market Competition

    Major companies operating in the gestational diabetes market are Sanofi S.A., Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Dexcom Inc, Biocon Limited, Ascensia Diabetes Care Holdings AG, Roche Diabetes Care, Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc, Ypsomed Holding AG, Beta Bionics Inc, Bigfoot Biomedical Inc, Glooko Inc, Philips Healthcare, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Novartis AG, Adocia SA, Daiichi Sankyo Company Ltd

    Access The Complete Gestational Diabetes Market Report:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    Gestational Diabetes Market Regional Distribution: Which Areas Drive Market Expansion?

    North Americawas the largest region in the gestational diabetes market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gestational Diabetes Market Expected To Reach $13.85 Billion By 2030 As Growth Accelerates At 8.7% CAGR

    Gestational Diabetes Market Expected To Reach $13.85 Billion By 2030 As Growth Accelerates At 8.7% CAGR

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Gestational Diabetes Market Value Analysis: What Growth Is Expected Over The Forecast Period?

    The market for gestational diabetes experienced robust expansion historically and is projected to continue its upward trajectory, expanding from $9.11 billion in 2025 to $9.93 billion in 2026, reflecting a compound annual growth rate of 8.9%. This growth during the past period is largely due to several key factors including rising obesity trends, an increase in pregnancies among older women, the implementation of early screening for diabetes, advancements in prenatal care services, and a heightened awareness of complications associated with pregnancy.

    The market for gestational diabetes is poised for significant expansion in the coming years, projected to reach $13.85 billion by 2030, driven by a compound annual growth rate of 8.7%. This projected increase during the forecast period is largely fueled by an escalating incidence of gestational diabetes, the proliferation of digital health monitoring solutions, enhancements in prenatal diagnostic capabilities, a heightened emphasis on preventative care for expectant mothers, and supportive healthcare policies. Key developments anticipated within this timeframe include a greater uptake of blood glucose monitoring systems, augmented utilization of insulin therapy for pregnant individuals, a growing emphasis on managing this condition through lifestyle modifications, the broadening of prenatal screening initiatives, and elevated awareness surrounding maternal health.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

    Gestational Diabetes Market Development Factors: Which Trends Are Supporting Demand?

    The expanding segment of the population classified as obese, characterized by a body mass index (BMI) of 30 or greater and signifying substantial body fat, is poised to be a significant catalyst for the expansion of the gestational diabetes market. This surge in obesity rates is attributable to a confluence of factors including predominantly inactive lifestyles, a greater reliance on energy-dense, processed food items, inherent genetic tendencies, and restricted availability of nutritious food choices and physical activity venues. The management of gestational diabetes holds particular importance for this demographic, given their heightened susceptibility to insulin resistance and accelerated weight gain during pregnancy, scenarios that can precipitate adverse outcomes for both the expectant mother and the developing fetus if not properly addressed. Illustrating this trend, data from the Office for Health Improvement and Disparities, a UK governmental organization, indicated that in England, a notable 64.5% of individuals aged 18 and above were either overweight or obese between 2023 and 2024, a slight increase from the 64.0% recorded in the preceding year (2022-2023). Consequently, the growing prevalence of obesity is a primary determinant in the upward trajectory of the gestational diabetes market.

    Gestational Diabetes Market Segment Landscape: Which Areas Lead Market Development?

    The gestational diabetes market covered in this report is segmented –

    1) By Type: Type A1, Type A2, Other Types

    2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological Treatment

    3) By Administration: Oral, Intravenous, Other Administrations

    4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers

    Subsegments:

    1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes

    2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes

    3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications

    Gestational Diabetes Market Transformation Trends: Which Innovations Are Driving Change?

    Within the gestational diabetes market, leading enterprises are prioritizing the creation of cutting-edge solutions, specifically diagnostic kits, to facilitate swift, precise, and user-friendly early identification of the condition; these kits serve as vital medical instruments for quantifying blood sugar levels and pinpointing instances of impaired glucose tolerance in expectant mothers, thereby supporting prompt diagnosis and effective management. Illustratively, in August of 2024, DirectSens GmbH, a biotechnology firm headquartered in Austria, introduced the XpressGT RUO kit, a diagnostic device engineered for the detection of gestational diabetes, alongside conditions like endometriosis, insulin resistance, and liver ailments, which gauges 2-hydroxybutyrate (2-HB) concentrations in venous blood with high accuracy; this metabolite, a natural byproduct of liver activity, can escalate due to reductive stress, a factor implicated in numerous endocrine and obesity-related health issues, including insulin resistance, and the kit’s compatibility with any standard clinical analyzer enables the generation of results within an impressive 8-minute timeframe, presenting a remarkably expedient diagnostic capability.

    Gestational Diabetes Market Industry Leaders And Market Competition

    Major companies operating in the gestational diabetes market are Sanofi S.A., Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Dexcom Inc, Biocon Limited, Ascensia Diabetes Care Holdings AG, Roche Diabetes Care, Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc, Ypsomed Holding AG, Beta Bionics Inc, Bigfoot Biomedical Inc, Glooko Inc, Philips Healthcare, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Novartis AG, Adocia SA, Daiichi Sankyo Company Ltd

    Access The Complete Gestational Diabetes Market Report:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    Gestational Diabetes Market Regional Distribution: Which Areas Drive Market Expansion?

    North Americawas the largest region in the gestational diabetes market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gestational Diabetes Market Shaped by Advances in Diagnostic Solutions

    Gestational Diabetes Market Shaped by Advances in Diagnostic Solutions

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Large Will The Gestational Diabetes Market Be By 2030 Compared To Its 2026 Market Size?

    The gestational diabetes market size has demonstrated strong expansion in recent years. It is anticipated to increase from $9.11 billion in 2025 to $9.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.9%. Historically, this growth can be ascribed to elements such as escalating obesity rates, a rise in pregnancies at higher maternal ages, the establishment of early diabetes screening programs, an increase in prenatal care services, and heightened awareness of pregnancy complications.

    The gestational diabetes market is projected to experience substantial expansion in the coming years, anticipated to reach $13.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. The anticipated growth over the forecast period is primarily driven by factors such as the increasing prevalence of gestational diabetes, the widening adoption of digital health monitoring, advancements in prenatal diagnostics, a greater emphasis on preventive maternal care, and supportive healthcare policies. Key trends observed during this period encompass the increasing acceptance of blood glucose monitoring, a rise in the application of insulin therapy during pregnancy, an evolving focus on lifestyle-centric disease management, the proliferation of prenatal screening initiatives, and heightened maternal health awareness.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    What Significant Factors Are Influencing The Gestational Diabetes Market Expansion?

    The growing number of individuals classified as obese is anticipated to fuel expansion in the gestational diabetes market. This demographic includes persons with a body mass index (BMI) of 30 or above, signifying unhealthy levels of body fat that can lead to serious health concerns. The increase in obesity stems from several factors, such as inactive lifestyles, higher intake of calorie-dense, processed foods, hereditary tendencies, and insufficient availability of nutritious food and opportunities for physical activity. Managing gestational diabetes is vital for obese individuals as their elevated susceptibility to insulin resistance and significant weight gain during gestation can result in adverse outcomes for both the mother and the infant if not properly addressed. For example, data released in May 2025 by the Office for Health Improvement and Disparities, a UK government organization, indicated that between 2023 and 2024, approximately 64.5% of adults aged 18 and over in England were either overweight or obese, an increase from 64.0% recorded from 2022 to 2023. Consequently, the expanding obese population is acting as a primary driver for the gestational diabetes market.

    How Is The Gestational Diabetes Market Categorized Across Its Segment Groups?

    The gestational diabetes market covered in this report is segmented –

    1) By Type: Type A1, Type A2, Other Types

    2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological Treatment

    3) By Administration: Oral, Intravenous, Other Administrations

    4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers

    Subsegments:

    1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes

    2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes

    3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications

    What Trends Are Affecting The Direction Of The Gestational Diabetes Market?

    Companies in the gestational diabetes market are concentrating on creating technologically advanced products, such as diagnostic kits for gestational diabetes, to offer quick, accurate, and convenient methods for early detection. A diagnostic kit for gestational diabetes is a medical instrument used to gauge blood glucose levels and identify atypical glucose tolerance in pregnant women, thereby assisting in the prompt discovery and management of the condition. For instance, in August 2024, DirectSens GmbH, an Austria-based biotechnology company, introduced the XpressGT RUO kit, a diagnostic kit designed for the diagnosis of gestational diabetes, endometriosis, insulin resistance, and liver disease. This kit accurately measures 2-hydroxybutyrate (2-HB) levels found in venous blood, which are naturally produced by the liver during its normal functions. Elevated 2-HB levels are linked to increased reductive stress, which is associated with various endocrine and obesity-related disorders, including insulin resistance. The kit is compatible with any existing clinical analyzer and provides results in just 8 minutes, presenting a rapid and efficient diagnostic solution.

    Which Firms Are Influencing Competition In The Gestational Diabetes Market?

    Major companies operating in the gestational diabetes market are Sanofi S.A., Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Dexcom Inc, Biocon Limited, Ascensia Diabetes Care Holdings AG, Roche Diabetes Care, Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc, Ypsomed Holding AG, Beta Bionics Inc, Bigfoot Biomedical Inc, Glooko Inc, Philips Healthcare, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Novartis AG, Adocia SA, Daiichi Sankyo Company Ltd

    Get The Full Gestational Diabetes Market Report:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    Which Region Holds The Highest Market Share In The Gestational Diabetes Market?

    North America was the largest region in the gestational diabetes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Gestational Diabetes Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    Browse Through More Reports Similar to the Global Gestational Diabetes Market 2026, By The Business Research Company

    Diabetes Care Devices Market 2026

    https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

    Type 1 Diabetes Market Report 2026

    https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

    Insuman Market Report 2026

    https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • A key trend shaping the Gestational Diabetes Market involves the Advancements In Diagnostic Solutions For Early Detection Of Health Conditions

    A key trend shaping the Gestational Diabetes Market involves the Advancements In Diagnostic Solutions For Early Detection Of Health Conditions

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Size Increase Is Anticipated For The Gestational Diabetes Market Over The 2026–2030 Period?

    The gestational diabetes market has experienced robust expansion in recent years. Its size is projected to grow from $9.11 billion in 2025 to $9.93 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.9%. This growth observed historically is attributable to factors such as increasing obesity rates, a rise in pregnancies among older mothers, the implementation of early diabetes screening programs, the expansion of prenatal care services, and greater awareness of pregnancy complications.

    The gestational diabetes market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $13.85 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.7%. This projected growth can be attributed to several factors, including the increasing prevalence of gestational diabetes, the widening adoption of digital health monitoring, advancements in prenatal diagnostics, a greater emphasis on preventive maternal care, and supportive healthcare policies. During this period, major trends are expected to involve the rising adoption of blood glucose monitoring, a greater utilization of insulin therapy during pregnancy, an increased focus on lifestyle-based disease management, the expansion of prenatal screening programs, and improved awareness concerning maternal health.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

    What Underlying Factors Are Accelerating The Growth Of The Gestational Diabetes Market?

    The projected expansion of the gestational diabetes market is anticipated to be fueled by the growing number of obese individuals. Obese individuals are defined as those with a body mass index (BMI) of 30 or above, signifying excessive body fat levels that could lead to considerable health concerns. This demographic is growing as a result of factors such as inactive lifestyles, increased intake of processed, high-calorie foods, genetic factors, and restricted availability of nutritious food and opportunities for physical activity. Addressing gestational diabetes is vital for obese individuals, given their heightened susceptibility to insulin resistance and significant weight gain during gestation, which, if not controlled, can result in adverse outcomes for both the pregnant individual and the infant. As an illustration, data from May 2025 released by the Office for Health Improvement and Disparities, a UK-based government body, showed that approximately 64.5% of adults aged 18 and above in England were classified as overweight or living with obesity between 2023 and 2024, an increase from 64.0% recorded from 2022 to 2023. Consequently, the expanding obese population is a key factor propelling the gestational diabetes market.

    How Is The Gestational Diabetes Market Segmented Across Key Categories?

    The gestational diabetes market covered in this report is segmented –

    1) By Type: Type A1, Type A2, Other Types

    2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological Treatment

    3) By Administration: Oral, Intravenous, Other Administrations

    4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers

    Subsegments:

    1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes

    2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes

    3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications

    How Are Trends Transforming The Gestational Diabetes Market Landscape?

    Leading companies in the gestational diabetes market are focused on developing technologically advanced offerings, such as diagnostic kits specifically for gestational diabetes, to provide quick, precise, and convenient early detection methods. A diagnostic kit for gestational diabetes is a medical device utilized to measure blood glucose levels and identify abnormal glucose tolerance in pregnant women, thereby aiding in the early diagnosis and management of the condition. For example, in August 2024, DirectSens GmbH, an Austria-based biotechnology company, introduced the XpressGT RUO kit, a diagnostic tool designed to identify gestational diabetes, endometriosis, insulin resistance, and liver disease. This kit accurately measures 2-hydroxybutyrate (2-HB) levels present in venous blood, which is naturally produced by the liver during its standard functions. Elevated 2-HB levels are linked to increased reductive stress, which is associated with various endocrine and obesity-related disorders, including insulin resistance. The kit is compatible with any existing clinical analyzer and provides results in just 8 minutes, presenting a fast and efficient diagnostic solution.

    Who Are The Dominant Players Shaping The Gestational Diabetes Market Landscape?

    Major companies operating in the gestational diabetes market are Sanofi S.A., Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Dexcom Inc, Biocon Limited, Ascensia Diabetes Care Holdings AG, Roche Diabetes Care, Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc, Ypsomed Holding AG, Beta Bionics Inc, Bigfoot Biomedical Inc, Glooko Inc, Philips Healthcare, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Novartis AG, Adocia SA, Daiichi Sankyo Company Ltd

    Read the full gestational diabetes market report here:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    Which Region Is Projected To Dominate The Gestational Diabetes Market During The Forecast Period?

    North America was the largest region in the gestational diabetes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Gestational Diabetes Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=20818&type=smp

    Browse Through More Reports Similar to the Global Gestational Diabetes Market 2026, By The Business Research Company

    Tumor Infiltrating Lymphocytes Global Market Report

    https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

    Emphysema Global Market Report

    https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

    Non Hodgkin Lymphoma Nhl Global Market Report

    https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Gestational Diabetes Market Forecast 2026–2035: Long-Term Growth Insights

    Global Gestational Diabetes Market Forecast 2026–2035: Long-Term Growth Insights

    Uncover key drivers, emerging technologies, and competitive movements shaping the gestational diabetes market from 2026–2035 with trusted insights from The Business Research Company

    What size range is anticipated for the Gestational Diabetes Market from 2026 to 2030?

    The gestational diabetes market has experienced substantial growth in recent years. This market is anticipated to expand from $9.11 billion in 2025 to $9.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.9%. Historically, this growth has been fueled by factors such as increasing obesity rates, a rise in pregnancies among older mothers, the availability of early diabetes screening programs, the expansion of prenatal care services, and a greater awareness of pregnancy complications.

    The gestational diabetes market is projected to experience substantial expansion in the coming years, reaching a valuation of $13.85 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.7%. This anticipated growth throughout the forecast period is primarily due to factors such as an increase in gestational diabetes prevalence, broader adoption of digital health monitoring, advancements in prenatal diagnostics, a greater emphasis on preventive maternal care, and supportive healthcare policies. Key developments anticipated during this timeframe include an uptick in the use of blood glucose monitoring, a rise in insulin therapy for pregnant individuals, an increasing focus on managing the disease through lifestyle modifications, the expansion of prenatal screening initiatives, and heightened awareness regarding maternal health.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

    What Drivers Are Affecting Demand In The Gestational Diabetes Market?

    The increasing obese population is anticipated to propel the growth of the gestational diabetes market in the future. This population consists of individuals with a body mass index (BMI) of 30 or higher, indicating excess body fat that poses considerable health risks. The rise in the obese population is attributed to a combination of sedentary lifestyles, increased consumption of high-calorie, processed foods, genetic predispositions, and limited access to healthy food and exercise options. Gestational diabetes treatment is critical for the obese population because their heightened risk of insulin resistance and significant weight gain during pregnancy can lead to complications for both mother and baby if not managed. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity from 2023 to 2024, an increase from 64.0% in 2022 to 2023. Therefore, the expanding obese population is driving the gestational diabetes market.

    Which Segments Are Gaining Traction In The Gestational Diabetes Market?

    The gestational diabetes market covered in this report is segmented –

    1) By Type: Type A1, Type A2, Other Types

    2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological Treatment

    3) By Administration: Oral, Intravenous, Other Administrations

    4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers

    Subsegments:

    1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes

    2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes

    3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications

    How Are Emerging Trends Affecting The Progression Of The Gestational Diabetes Market?

    Key players within the gestational diabetes market are prioritizing the development of technologically advanced products, including diagnostic kits for gestational diabetes, aiming to offer swift, accurate, and user-friendly approaches for early detection. A diagnostic kit for gestational diabetes functions as a medical device employed to gauge blood glucose levels and pinpoint atypical glucose tolerance in pregnant women, thereby aiding in the early identification and management of the condition. As an illustration, in August 2024, DirectSens GmbH, an Austria-based biotechnology company, launched the XpressGT RUO kit, a diagnostic solution specifically created to diagnose gestational diabetes, endometriosis, insulin resistance, and liver disease. It precisely measures 2-hydroxybutyrate (2-HB) levels present in venous blood, which the liver naturally produces during its normal operations. Elevated 2-HB levels are connected to increased reductive stress, which is associated with various endocrine and obesity-related disorders, such as insulin resistance. This kit is compatible with any existing clinical analyzer and delivers results in merely 8 minutes, offering a rapid and effective diagnostic alternative.

    Who Are The Major Companies Operating In The Gestational Diabetes Market?

    Major companies operating in the gestational diabetes market are Sanofi S.A., Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Dexcom Inc, Biocon Limited, Ascensia Diabetes Care Holdings AG, Roche Diabetes Care, Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc, Ypsomed Holding AG, Beta Bionics Inc, Bigfoot Biomedical Inc, Glooko Inc, Philips Healthcare, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Novartis AG, Adocia SA, Daiichi Sankyo Company Ltd

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    Which Region Is Anticipated To See The Fastest Growth In The Gestational Diabetes Market?

    North America was the largest region in the gestational diabetes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Gestational Diabetes Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=20818&type=smp

    Browse Through More Reports Similar to the Global Gestational Diabetes Market 2026, By The Business Research Company

    Diabetes Care Devices Market 2026

    https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

    Type 1 Diabetes Market Report 2026

    https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

    Insuman Market Report 2026

    https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gestational Diabetes Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029

    Gestational Diabetes Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What Is The Projected Valuation Of The Gestational Diabetes Market In The Coming Years?

    In recent times, the gestational diabetes sector has experienced robust expansion. The market is projected to proliferate from a worth of $8.37 billion in 2024 to a value of $9.11 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.9%. Factors such as heightened risk of diabetes, enhanced precision in measuring blood glucose levels, the proliferation of insurance providers, a surge in the number of diabetic patients, and a mounting diabetes populace have contributed to this historic period’s growth.

    Anticipations imply a robust expansion of the gestational diabetes market size in the upcoming years, with estimated growth reaching $12.78 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this forecasted growth include an increasing obesity rate, the emerging acceptance of cloud-based project strategies, expanding utilization of relevant devices and applications, a rising trend of diabetes owing to unhealthy lifestyle choices, and heightened public health awareness. The forthcoming period will also witness major trends like digital diabetes management applications, closed-loop control systems, diabetes management technology, enzymatic technology, and cutting-edge medical technologies.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

    What Drivers Are Accelerating Expansion Of The Gestational Diabetes Market?

    The rise in obesity is believed to be spurring the expansion of the gestational diabetes market. Such individuals have a body mass index (BMI) of 30 or above, indicative of an excess of body fat that could pose significant health hazards. The increase in obesity is a result of a range of factors including sedentary lifestyles, consumption of high-calorie processed foods, genetic factors, and restricted access to healthy food and exercise opportunities. For obese individuals, treating gestational diabetes is vital as they have a higher risk of insulin resistance and excessive pregnancy weight gain, both of which could cause complications for the mother and child if not properly managed. As per the data provided by the World Health Organization in March 2024, about 1 in 8 people worldwide were obese in 2022, with around 2.5 billion adults over 18 categorized as overweight. This number included 890 million obese individuals. Among adults, 43% were overweight and 16% were obese. Moreover, 37 million children below 5 years old were overweight, while over 390 million children and adolescents between 5-19 years were overweight; 160 million of them were obese. Consequently, the growing obesity rate is a catalyst for the gestational diabetes market.

    How Is The Global Gestational Diabetes Market Broken Down By Segment?

    The gestational diabetesmarket covered in this report is segmented –

    1) By Types: Type A1; Type A2; Other Types

    2) By Treatment: Monitoring; Drug Treatment; Non-pharmacological treatment

    3) By Administration: Oral; Intravenous; Other Administrations

    4) By End User: Hospitals; Clinics; Home Care Settings; Diagnostic Centers

    Subsegments:

    1) By Type A1: Diet-Controlled Gestational Diabetes; Exercise-Controlled Gestational Diabetes

    2) By Type A2: Insulin-Controlled Gestational Diabetes; Oral Medication-Controlled Gestational Diabetes

    3) By Other Types: Pre-Gestational Diabetes; Gestational Diabetes With Complications

    Which Trends Are Likely To Redefine Growth Paths In The Gestational Diabetes Market?

    Key players in the gestational diabetes market are concentrating on innovating and creating advanced technological products like diagnostic kits for gestational diabetes, designed for swift, precise, and user-friendly methods of early detection. The principal function of a gestational diabetes diagnostic kit is to determine blood glucose levels and detect any irregular glucose tolerance in expectant women, which facilitates early detection and control of the disease. For instance, DirectSens GmbH, a biotech firm based in Austria, introduced the XpressGT RUO kit in August 2024. This diagnostic kit is intended to diagnose conditions like gestational diabetes, endometriosis, insulin resistance, and liver ailment by accurately measuring 2-hydroxybutyrate (2-HB) levels present in venous blood, a byproduct of liver’s normal activities. Elevated 2-HB levels are connected to a rise in reductive stress, which is tied to several endocrine and obesity-related disorders including insulin resistance. With compatibility to any existing clinical analyzer and the ability to provide results within just 8 minutes, this kit proves to be a practical and efficient diagnostic solution.

    Which Firms Are Making The Biggest Impact In The Gestational Diabetes Market?

    Major companies operating in the gestational diabetes market are Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Dexcom Inc, Biocon Limited, LifeScan Inc, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Nipro Diagnostics, Inc., Sernova Corp., ZyVersa Therapeutics, Inc., Peptron Inc., Roche Diabetes Care, DiabetOmics Inc, Merck & Co. Inc., Medtronic plc

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    Which Geographic Regions Are Creating Strong Demand In The Gestational Diabetes Market?

    North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=20818&type=smp

    Browse Through More Reports Similar to the Global Gestational Diabetes Market 2025, By The Business Research Company

    Diabetes Care Devices Market 2025

    https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

    Diabetes Therapies Market 2025

    https://www.thebusinessresearchcompany.com/report/diabetes-therapies-market

    Digital Diabetes Management Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/digital-diabetes-management-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gestational Diabetes Market to Grow at a CAGR of 8.8% from 2025 to 2029

    Gestational Diabetes Market to Grow at a CAGR of 8.8% from 2025 to 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    #What Are The Current (2025) And Forecast (2029) Sizes Of The Gestational Diabetes Market?

    The gestational diabetes market has seen substantial growth recently. It is projected to increase from $8.37 billion in 2024 to $9.11 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.9%. This past growth can be attributed to factors such as an elevated risk of diabetes, enhanced accuracy in measuring blood glucose levels, a rise in the number of insurance providers, and an expanding population of diabetic patients.

    The gestational diabetes market is anticipated to show strong expansion in the coming years, projected to reach $12.78 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.8%. This growth during the forecast period is attributed to factors such as an increase in obesity rates, the growing acceptance of cloud-based project arrangements, the expanding utilization of related devices and applications, the increasing prevalence of diabetes due to unhealthy lifestyles, a rise in public health consciousness, and escalating diabetes prevalence rates. Prominent trends for this period include digital diabetes management apps, closed-loop control systems, advancements in diabetes management technology, enzymatic technology, and innovative medical technologies.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

    What Are The Key Drivers Of Growth In The Gestational Diabetes Market?

    The expanding obese population is projected to stimulate the growth of the gestational diabetes market moving forward. The obese population refers to individuals with a body mass index (BMI) of 30 or greater, signifying an excess of body fat that can present considerable health dangers. This population is growing as a result of a mix of inactive lifestyles, greater intake of high-calorie, processed foods, genetic factors, and restricted availability of nutritious food and exercise alternatives. Addressing gestational diabetes is vital for the obese population because their elevated likelihood of insulin resistance and substantial weight gain during pregnancy can cause health issues for both the mother and infant if not managed. For instance, in March 2024, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that around 1 in 8 people worldwide were affected by obesity in 2022, with 2.5 billion adults aged 18 and older categorized as overweight, a figure that includes 890 million individuals living with obesity. Among adults, 43% were overweight, and 16% were living with obesity. Furthermore, 37 million children under the age of 5 were overweight, while more than 390 million children and adolescents aged 5–19 years were overweight, with 160 million of those living with obesity. Consequently, the rising obese population is propelling the gestational diabetes market.

    How Is The Gestational Diabetes Market Classified Into Different Segments?

    The gestational diabetesmarket covered in this report is segmented –

    1) By Types: Type A1; Type A2; Other Types

    2) By Treatment: Monitoring; Drug Treatment; Non-pharmacological treatment

    3) By Administration: Oral; Intravenous; Other Administrations

    4) By End User: Hospitals; Clinics; Home Care Settings; Diagnostic Centers

    Subsegments:

    1) By Type A1: Diet-Controlled Gestational Diabetes; Exercise-Controlled Gestational Diabetes

    2) By Type A2: Insulin-Controlled Gestational Diabetes; Oral Medication-Controlled Gestational Diabetes

    3) By Other Types: Pre-Gestational Diabetes; Gestational Diabetes With Complications

    Which Ongoing Trends Are Expected To Shape The Gestational Diabetes Market Outlook?

    Leading companies in the gestational diabetes market are concentrating on developing sophisticated technological products, such as diagnostic kits specifically for gestational diabetes, to offer quick, accurate, and convenient solutions for early identification. A diagnostic kit for gestational diabetes functions as a medical device that measures blood glucose levels and detects abnormal glucose tolerance in pregnant women, thereby supporting the condition’s early detection and ongoing management. For example, in August 2024, DirectSens GmbH, an Austria-based biotechnology company, unveiled the XpressGT RUO kit, a diagnostic kit engineered to diagnose gestational diabetes, endometriosis, insulin resistance, and liver disease. It precisely measures 2-hydroxybutyrate (2-HB) levels found in venous blood, which is naturally produced by the liver during its regular functions. Elevated 2-HB levels are linked to increased reductive stress, a factor associated with various endocrine and obesity-related disorders, including insulin resistance. The kit is compatible with any existing clinical analyzer and yields results in merely 8 minutes, presenting a swift and effective diagnostic solution.

    Who Are The Primary Competitors In The Global Gestational Diabetes Market?

    Major companies operating in the gestational diabetes market are Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Dexcom Inc, Biocon Limited, LifeScan Inc, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Nipro Diagnostics, Inc., Sernova Corp., ZyVersa Therapeutics, Inc., Peptron Inc., Roche Diabetes Care, DiabetOmics Inc, Merck & Co. Inc., Medtronic plc

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    What Are The Key Regional Factors Influencing The Gestational Diabetes Market Growth?

    North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Gestational Diabetes Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=20818&type=smp

    Browse Through More Reports Similar to the Global Gestational Diabetes Market 2025, By The Business Research Company

    Diabetes Care Devices Market 2025

    https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

    Diabetes Therapies Market 2025

    https://www.thebusinessresearchcompany.com/report/diabetes-therapies-market

    Digital Diabetes Management Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/digital-diabetes-management-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Strong CAGR to Propel in the Gestational Diabetes Market and Beyond upto $12.78 Billion by 2029

    Strong CAGR to Propel in the Gestational Diabetes Market and Beyond upto $12.78 Billion by 2029

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has The Gestational Diabetes Market Size Shifted, And What Is the Outlook Through 2034?

    There has been a robust expansion in the market size of gestational diabetes in the past few years. The market is projected to increase from $8.37 billion in 2024 to reach $9.11 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%. The growth witnessed in the historic period is credited to factors such as the escalating risk of diabetes, an improvement in the precision of measuring blood glucose levels, a rise in the number of insurance providers, and a surge in the demographic of diabetic patients, underlining the escalating diabetes prevalence.

    In the upcoming years, the market size for gestational diabetes is anticipated to experience robust growth. The market is likely to expand to$12.78 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.8%. This escalation during the forecast period can be primarily accredited to factors such as the rising obesity rates, growing adoption of cloud-based project solutions, and an increase in the use of related devices and applications. An unhealthy lifestyle leading to a higher incidence of diabetes, increased awareness about public health, and rising prevalence of diabetes also contribute to this growth. Looking ahead, major trends set to dominate the forecast period include digital apps for diabetes management, closed-loop control systems, technology for diabetes management, enzymatic technology and groundbreaking medical technologies.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

    Which Primay Drivers Are Accelerating Growth in the Gestational Diabetes Market?

    The growth of the gestational diabetes market is projected to be driven by the increasing rate of obesity. Individuals who possess a body mass index (BMI) of 30 or higher, therefore having a high amount of body fat that could cause numerous health problems, are considered obese. The rise in obesity is a result of factors like sedentary lifestyles, the intake of high-calorie processed food, genetic factors, along with limited accessibility to healthy food and exercise options. Treatment for gestational diabetes is paramount for obese individuals as their higher tendencies towards insulin resistance and excessive weight gain during pregnancy could potentially cause issues for both the mother and child if not properly addressed. For example, as per the World Health Organization, a Switzerland-based intergovernmental organization, in March 2024, it was indicated that 1 in 8 people worldwide in 2022 were living with obesity. This included a staggering 2.5 billion adults over the age of 18, who were categorized as overweight, among which was a further subset of 890 million individuals dealing with obesity. Among this group, 43% were overweight while 16% were living with obesity. Additionally, 37 million children under 5 years were overweight, with over 390 million children and youngsters between the ages of 5–19 years also overweight, of which 160 million were living with obesity. As such, the continual rise in obesity rates is fueling the growth of the gestational diabetes market.

    Which Primary Segments of the Gestational Diabetes Market Are Driving Growth and Industry Transformations?

    The gestational diabetesmarket covered in this report is segmented –

    1) By Types: Type A1; Type A2; Other Types

    2) By Treatment: Monitoring; Drug Treatment; Non-pharmacological treatment

    3) By Administration: Oral; Intravenous; Other Administrations

    4) By End User: Hospitals; Clinics; Home Care Settings; Diagnostic Centers

    Subsegments:

    1) By Type A1: Diet-Controlled Gestational Diabetes; Exercise-Controlled Gestational Diabetes

    2) By Type A2: Insulin-Controlled Gestational Diabetes; Oral Medication-Controlled Gestational Diabetes

    3) By Other Types: Pre-Gestational Diabetes; Gestational Diabetes With Complications

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=20818&type=smp

    Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Gestational Diabetes Market?# Market?

    North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Which Technological Trends Are Reshaping the Gestational Diabetes Industry Dynamics?

    Leading firms in the gestational diabetes market are honing their focus on creating technologically superior products such as diagnostic kits for gestational diabetes. This focus is geared towards providing speedy, precise, and simple ways for early detection. The diagnostic kit for gestational diabetes serves as a medical instrument that gauges blood glucose levels, subsequently identifying abnormal glucose tolerance in expectant women. This aids in the prompt identification and control of the condition. Take, for example, DirectSens GmbH, a biotech company based in Austria, which in August 2024 unveiled the XpressGT RUO kit. This kit, intended to diagnose conditions such as gestational diabetes, endometriosis, insulin resistance, and liver disease, precisely measures 2-hydroxybutyrate (2-HB) levels. These levels are naturally found in venous blood, the byproduct of normal liver functions. Increased 2-HB levels typically suggest more reductive stress, which is associated with varying endocrine and obesity-related disorders, including insulin resistance. Compatible with any clinical analyzer currently available, the kit offers results in merely 8 minutes, proposing an effective and quick diagnostic alternative.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    What Parameters Are Used to Define the Gestational Diabetes Market?

    Gestational diabetes is a type of diabetes that develops during pregnancy when the body cannot produce enough insulin to regulate blood sugar levels effectively. This condition typically occurs in the second or third trimester and can affect women who have no prior history of diabetes. Gestational diabetes poses risks to both the mother and baby, including high birth weight, preterm birth, and potential development of type 2 diabetes later in life for both. It is often managed through dietary adjustments, exercise, blood sugar monitoring, and sometimes insulin therapy to ensure a healthy pregnancy and delivery.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20818

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gestational Diabetes Market Outlook 2025 – Insights for Executive and Strategic Planning

    Gestational Diabetes Market Outlook 2025 – Insights for Executive and Strategic Planning

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Gestational Diabetes Market Grown from 2024 to 2025?

    In recent times, there has been a robust expansion in the market size of gestational diabetes. The market is projected to escalate from $8.37 billion in 2024 to $9.14 billion in 2025, showing a compound annual growth rate (CAGR) of 9.3%. Various factors like a growing risk of diabetes, better precision in the measurement of blood glucose levels, an increased count of insurance providers, a rise in the number of diabetic patients and an overall surge in the diabetic population have contributed to the historic period growth.

    What Growth Rate Is Anticipated for the Gestational Diabetes Market in the Coming Years?

    Expectations are high for robust expansion in the gestational diabetes market over the coming years. By 2029, the market is forecasted to proliferate to $12.90 billion, boasting a compound annual growth rate (CAGR) of 9.0%. This anticipated growth trajectory during the prediction period can be credited to several factors, such as the escalating prevalence of obesity, growing adoption of cloud-based project setups, expanding use of relevant devices and applications, the rising instances of diabetes due to poor lifestyle choices, heightened public health awareness, and increasing diabetes prevalence rates. The prediction period is also expected to see significant trends including digital apps for managing diabetes, closed-loop control systems, diabetes management technologies, enzymatic technologies, and groundbreaking medical technologies.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

    Who Are the Leading Companies in the Gestational Diabetes Market?

    Major companies operating in the gestational diabetes market are Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Dexcom Inc, Biocon Limited, LifeScan Inc, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Nipro Diagnostics, Inc., Sernova Corp., ZyVersa Therapeutics, Inc., Peptron Inc., Roche Diabetes Care, DiabetOmics Inc, Merck & Co. Inc., Medtronic plc

    What Are the Key Drivers of the Gestational Diabetes Market?

    The expanding population experiencing obesity is seen as a significant driver for the growth of the gestational diabetes market. These individuals, with their Body Mass Index (BMI) hitting 30 or more, have excessive body fat, potentially leading to severe health issues. The causes for this obesity spike are inactive lifestyles, a higher intake of processed, high-calorie food, genetic predispositions, and restricted access to healthier food and exercise options. Those suffering from obesity are more at risk for gestational diabetes as their higher probability of insulin resistance and extreme weight gain during pregnancy could affect the mother and the child if not handled timely. Concretely, in March 2024, the World Health Organization, a Switzerland-based intergovernmental organization, stated that about one in eight people globally were considered obese in 2022, including 2.5 billion adults aged 18 and above, with 890 million of them classified as obese. Around 43% of adults were overweight and 16% were obese. Furthermore, 37 million children under the age of 5 were overweight, and over 390 million children and adolescents aged between 5-19 years were overweight, which included 160 million who were obese. Thus, the burgeoning obesity epidemic is fuelling the growth of the gestational diabetes market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=20818&type=smp

    What Are the Key Market Segments in the Gestational Diabetes Industry?

    The gestational diabetes market covered in this report is segmented –

    1) By Types: Type A1, Type A2, Other Types

    2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological treatment

    3) By Administration: Oral, Intravenous, Other Administrations

    4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers

    Subsegments:

    1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes

    2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes

    3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications

    What Are the Latest Trends in the Gestational Diabetes Market?

    Leading firms in the gestational diabetes market are prioritizing the advancement of technology in their products. Their focus is mainly on diagnostic kits for gestational diabetes, aimed at providing swift, precise, and accessible solutions for early detection. These kits are essential medical tools used to examine blood glucose concentrations and detect irregular glucose tolerance in expectant mothers, contributing to the premature identification and management of the disease. In August 2024, for instance, DirectSens GmbH, a biotechnology firm based in Austria, introduced the XpressGT RUO kit. This diagnostic kit is engineered to detect gestational diabetes, endometriosis, insulin resistance, and liver disease by accurately gauging the levels of 2-hydroxybutyrate (2-HB) in venous blood. This chemical is naturally produced by the liver during regular activities. High 2-HB levels signify increased reductive stress, which is correlated to various endocrine and obesity-related ailments, including insulin resistance. This kit is adaptable to any existing clinical analyzer, providing results within just 8 minutes for a speedy and effective diagnostic approach.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

    What Are the Key Regional Markets in the Gestational Diabetes Industry?

    North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20818

    This Report Delivers Insight On:

    1. How big is the gestational diabetes market, and how is it changing globally?

    2. Who are the major companies in the gestational diabetes market, and how are they performing?

    3. What are the key opportunities and risks in the gestational diabetes market right now?

    4. Which products or customer segments are growing the most in the gestational diabetes market?

    5. What factors are helping or slowing down the growth of the gestational diabetes market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model